GleamWall
中文EN

BVS Bioventus Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1665988 · Fiscal year ends 12/31

Financial factors as of 2026-09-26 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.9%
TTM net income YoY655.0%
TTM EPS YoY575.0%
Revenue 3-yr CAGR5.2%
Net income 3-yr CAGR—

Margins

Gross margin68.7%
Operating margin9.7%
Net margin9.8%
FCF margin14.5%
EBITDA margin14.0%

Returns

ROE28.2%
ROA8.3%
ROIC (approx.)12.8%
Asset turnover0.85x

Leverage & solvency

Liabilities / assets56.7%
Debt / equity0.96x
Current ratio1.68x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.53x
Accruals ratio-4.4%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-262026Q22026-06-272026Q12026-03-282025Q4*2025-12-312025Q32025-09-272025Q22025-06-282025Q12025-03-292024Q4*2024-12-31
Income statement
Revenue$142.44M$153.21M$132.09M$157.90M$138.65M$147.66M$123.88M$153.64M
Cost of revenue$45.31M$47.54M$41.32M$49.12M$44.42M$45.57M$40.82M$50.99M
Gross profit$97.13M$105.67M$90.77M$108.78M$94.23M$102.09M$83.06M$102.66M
R&D expense$3.44M$3.17M$2.47M$3.01M$2.92M$3.17M$3.01M$3.27M
SG&A expense$82.94M$82.74M$78.33M$82.76M$78.66M$79.11M$73.50M$86.87M
Operating income$9.70M$19.13M$8.42M$19.49M$11.25M$18.37M$4.87M$7.70M
Pretax income$6.16M$15.31M$4.52M$14.14M$4.67M$10.31M-$3.42M-$53,000
Income tax-$701,000-$20.90M$571,000-$3.17M$664,000$1.04M-$95,000$550,000
Net income$5.99M$33.44M$3.11M$14.76M$3.15M$7.46M-$2.64M-$388,000
EBITDA$10.75M$20.17M$19.62M$31.18M$12.65M$19.81M$16.73M$20.11M
EPS (basic)0.090.490.05—0.050.11-0.04—
EPS (diluted)0.080.470.04—0.050.11-0.04—
Weighted avg. shares (diluted)72.49M70.84M70.01M—68.84M68.54M66.01M—
Balance sheet
Cash & equivalents$30.71M$29.46M$35.85M$51.24M$42.16M$32.91M$22.80M$41.58M
Receivables$138.23M$138.41M$120.53M$128.30M$130.40M$132.37M$118.08M$127.39M
Inventory$83.10M$79.81M$83.19M$82.24M$96.27M$96.47M$94.05M$92.47M
Current assets$265.54M$257.53M$249.81M$272.84M$280.90M$275.20M$249.37M$275.61M
PP&E, net$19.78M$20.53M$21.29M$21.90M$22.98M$24.51M$25.72M$27.01M
Goodwill$7.46M$7.46M$7.46M$7.46M$7.46M$7.46M$7.46M$7.46M
Intangibles$343.93M$351.05M$359.66M$368.42M$377.40M$386.95M$395.73M$404.73M
Total assets$673.43M$673.35M$650.54M$683.56M$701.59M$706.79M$691.41M$727.96M
Current liabilities$157.70M$152.45M$148.09M$160.38M$161.75M$185.68M$174.75M$210.40M
Short-term debt$18.75M$18.75M$18.75M$15.00M$11.25M$43.36M$37.34M$27.34M
Long-term debt$211.08M$229.70M$253.33M$278.95M$311.33M$297.88M$308.59M$308.29M
Total debt$229.83M$248.45M$272.08M$293.95M$322.58M$341.24M$345.93M$335.63M
Total liabilities$381.56M$395.93M$416.27M$455.11M$494.34M$505.49M$505.94M$542.35M
Shareholders' equity$240.50M$228.31M$188.90M$184.10M$166.10M$161.24M$148.14M$147.94M
Net debt$199.12M$219.00M$236.23M$242.71M$280.42M$308.33M$323.13M$294.05M
Cash flow statement
Operating cash flow$20.66M$19.87M$8.93M$37.97M$30.10M$25.94M-$19.33M$19.32M
Capital expenditure$334,000$960,000$574,000$580,000$473,000$683,000$826,000$574,000
Free cash flow$20.32M$18.91M$8.36M$37.39M$29.62M$25.25M-$20.16M$18.75M
Investing cash flow-$1.83M-$2.46M-$574,000-$580,000-$473,000-$1.37M-$826,000$24.10M
Financing cash flow-$17.58M-$23.43M-$23.14M-$28.45M-$19.98M-$14.66M$947,000-$42.85M
Depreciation & amortization$1.05M$1.04M$11.21M$11.69M$1.40M$1.44M$11.87M$12.40M
Stock-based compensation$4.76M$4.77M$3.26M$3.44M$3.18M$3.36M$2.41M$2.02M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.